post-ASCT Consolidation
In Multiple Myeloma (MM)
Our autologous NK cells are administered immediately after autologous stem cell transplant (ASCT), acting as a cellular clean-up crew designed to eliminate residual disease and extend durable remissions.
A powerful consolidation therapy built for vulnerable patients.
Our NK cells are strategically deployed to do what NO OTHER therapy can.
post-ASCT Consolidation
In Multiple Myeloma
Our autologous NK cells are administered immediately after autologous stem cell transplant (ASCT), acting as a cellular clean-up crew designed to eliminate residual disease and extend durable remissions.
Lead Program: Multiple Myeloma
Clinical Setting
Consolidation therapy administered after autologous stem cell transplant (ASCT).
Therapeutic Mechanism
Infused NK cells repopulate the immune system, surveil residual tumor, and extend remission – potentially driving cures in this high-relapse setting.
Differentiation
First cell therapy explicitly designed to directly address the inevitable relapse post-ASCT; filling a desperate unmet medical need.
36,000
Multiple Myeloma
New US cases annually; 12,000 deaths per year in the US
8,000
ASCT Performed
40% of these patients relapse within 2 years, creating a desperate unmet need.
Market Impact: Establishing a new standard of immune maintenance in multiple myeloma
Compelling Phase 1 Clinical Results
Compelling safety and efficacy signals demonstrate the potential of our autologous NK cell platform in multiple myeloma patients.
6
Patients Enrolled
No Severe Adverse Events
75%
Response Rate
3/4 Evaluable Patients
100%
Survival
60+ Month Follow-Up
MRD
Deeping Observed
Granzyme B Spike
Key Clinical Insights
Efficacy Signals
- MRD deepening in 3 of 4 evaluable patients
- Sustained immune activation markers
- Durable response at 60-month follow-up
- Granzyme B elevation post-infusion
Safety Signals
- No grade 3+ adverse events attributed to treatment
- No cytokine release syndrome
- Well-tolerated across all dose levels
- Favorable pharmacokinetic profile
Other Programs
Advanced Bladder Cancer: Combination w/ Avelumab
Despite platinum chemo and avelumab (αPD-L1) maintenance, most advanced bladder cancer patients relapse quickly – creating a clear opportunity for NOK’s NK cells to boost PD-L1 response, extend survival, and drive cures in this setting.
